Ginkgo Biloba Doesn’t Prevent Dementia
Supplement Fails to Ward Off or Slow Alzheimer’s Disease in Large Study
WebMD News Archive
Nov. 18, 2008 -- Millions of older people take the herbal supplement ginkgo biloba in hopes that it will prevent or slow the progression of Alzheimer's disease and other age-related dementias, but one of the largest and longest studies to address the issue shows no benefit.
A little more than 3,000 elderly people who did not have Alzheimer's at the start of the study took either ginkgo biloba or a placebo for an average of six years.
In the Nov. 19 issue of The Journal of the American Medical Association, researchers report that the herbal supplement showed no evidence of reducing the overall incidence of either Alzheimer's disease or dementia.
"It was worth finding out if giving this relatively benign drug to older people would have an effect," study researcher Steven T. DeKosky, MD, tells WebMD. "But based on this research, ginkgo biloba cannot be recommended for preventing dementia."
DeKosky was with the University of Pittsburgh at the time of the study. He is now vice president and dean of the University of Virginia School of Medicine.
Ginkgo vs. Placebo
It is not clear how many people in the United States take ginkgo biloba, but sales of the supplement exceeded $249 million in 2006.
Earlier studies in older people with Alzheimer's disease or other age-related dementias have generally been disappointing.
A 2007 review of 35 such trials involving about 4,200 patients found "inconsistent and unconvincing" evidence of clinically significant benefits for the supplement in people with dementia.
None of the participants in the newly reported Ginkgo Evaluation of Memory (GEM) study had Alzheimer's at enrollment, although about 500 showed evidence of mild cognitive impairment.
In all, 3,069 people aged 75 or older took part in the trial. About half the volunteers took 120 milligrams of ginkgo biloba twice a day and the other half took a placebo. Neither the patients nor the researchers knew which treatment was being given.
Over an average of six years of follow-up, 523 study participants received a diagnosis of dementia, 246 (16%) in the placebo group and 277 (18%) in the ginkgo group.
The rate of Alzheimer's disease did not differ significantly between the two groups, with 3.3 cases occurring for every 100 people treated with ginkgo biloba each year, compared to 2.9 cases in the placebo group. The researchers also found no effect on the progression of mild cognitive impairment to dementia.